Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-03-30

FDA Approved: ONDANSETRON — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

View source ↗

Summary

FDA approved Glenmark Pharmaceuticals’ supplemental application for ondansetron (generic antiemetic) under ANDA077535.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ondansetron (ondansetron)

Snippet

SUPPL AP for ONDANSETRON (ONDANSETRON)